CS1 added to standard care for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial tests a new oral medication, called CS1, that is added to your current PAH medications. The goal is to see if it helps improve your symptoms and ability to exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You need a confirmed diagnosis of pulmonary arterial hypertension (PAH).
- You should have mild to moderate symptoms (WHO class II or III) — this means you may feel tired or short of breath with activity but not at rest.
- You must be already taking PAH medications for at least 90 days and keep the same dose.
- You need to be able to walk at least 150 meters (about a football field) and less than 550 meters in 6 minutes.
- You cannot have PAH caused by other lung, heart, or blood clot conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study tests whether spironolactone, a water pill that helps the heart and blood vessels, can improve symptoms in people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It's a phase 2 trial, meaning it's early but may offer a new treatment option.
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.